The histological manifestation of growth-regulating and differentiation-inducing signals in cancer cells is considered as a key component for clinical outcome prediction and commonly defined as tumor differentiation grade. However, the molecular and functional framework underlying this clinical parameter remains poorly understood. Our correlative data display a significant association (P40.001) between mitochondrial uncoupling protein 2 (UCP2) and tumor grade in primary breast cancer (n ¼ 234). Through mechanistic analyses, we show a synergistic link between UCP2 and established cellular pathways in conferring gradeassociated functional phenotypes. Here, the application of well to moderately differentiated primary tumor cell lines has enabled direct observation of SMAD recruitment to the UCP2 promoter underlying repression of gene transcription. In contrast, poorly differentiated tumor cells, known to be TGFb resistant, displayed aberrant UCP2 regulation, and consequently, gene overexpression, which reduced mitochondrial calcium and facilitated the maintenance of mitochondrial membrane potential, thereby significantly decreasing oxidative stress and inhibiting cell death. Conversely, UCP2 silencing in such cells rapidly led to the induction of apoptosis and cell differentiation, concurrent with reduced cell survival and proliferation, confirming genespecific effects. Demonstration of a biologically driven role for UCP2 dysregulation in promoting multiple characteristics of tumor aggressiveness strongly endorses assessment of gene expression at clinical presentation to augment therapeutic decision-making and improve patient outcome through personalized targeting approaches.
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derives its designation from its involvement in uncoupling oxidative phosphorylation and facilitating energy dissipation as heat. [2] [3] [4] Reports regarding UCP2 expression during tumorigenesis and chemotherapeutic resistance are just beginning to emerge. [5] [6] [7] Widely known as a negative regulator of mitochondrial reactive oxygen species (ROS) and mitochondria-mediated cell death, [8] [9] [10] [11] UCP2 function seems to be tissue specific (reviewed in Mattiasson and Sullivan 12 ). The detection of UCP2 overexpression in malignancy is presently limited to the colon. 5 Although no direct evidence exists for its role in cancer progression, it seems plausible that UCP2 assists in the adaptation and survival of tumor cells in an increasingly hostile tissue microenvironment. The impairment of myogenic differentiation induced by increased UCP2 levels 13 also suggests its contribution to cellular dedifferentiation during tumor evolution. Despite known physiological functions of UCP2, key regulatory pathways associated with its expression in human health and disease remain unidentified.
Unlike colon, breast cancer is characteristically diverse in its histological, molecular and clinical phenotype offering opportunities for improved disease stratification. In this regard, microscopically determined histological grade/differentiation status has long served an important role. On the basis of a histological evaluation of cell proliferation and differentiation, evident in tumor cross sections, primary tumors are assigned low (grade 1 or well differentiated), intermediate (grade 2 or moderately differentiated) or high (grade 3 or poorly differentiated) histological grade.
14 Grade 1 tumors are known to confer a relatively good clinical prognosis, whereas a significant proportion of grade 2 and 3 tumors lead to poor patient outcome. 15 More recent efforts toward reducing the subjectivity associated with microscopic grade determination through global expression profiling of tumor tissue have greatly improved the predictive accuracy of intermediate-grade tumors, and confirmed differential activation of cell cycle and proliferation-related genes (reviewed in Wirapati et al. 16 ). Our experimental design given here has assisted in revealing a previously unappreciated distinction in the UCP2 profiles of primary breast cancer of varying histological grades, providing novel insights regarding the biological underpinnings of tumor aggressiveness. We have observed a significant elevation of UCP2 levels in poorly differentiated breast cancer, implicating a pathophysiological role for its constitutive activation in such tumors. For a direct test of this assumption, experimentation with live model systems, which portray and maintain distinctive molecular profiles associated with histological grade, is a prerequisite. Widely available immortalized cell lines derived from high-grade primary and metastatic breast cancer, provide only a partial framework for this purpose. In conjunction with a unique series of authenticated cell lines derived from breast tumors of varying grades, 17, 18 functional changes associated with UCP2 overexpression have unveiled critical events, other than cell proliferation, in the divergence between well and poorly differentiated primary tumors. Toward defining a molecular basis for the differentiation status of primary breast cancer, we provide direct evidence for the crosstalk between UCP2 and the TGFb pathway through repressive SMAD binding elements (RSBEs), which trigger gene repression. 19 Our data show that intact TGFb/SMAD-dependent signaling tightly regulates UCP2 expression to maintain a relatively normalappearing, well-differentiated epithelial phenotype. In contrast, in TGFb-resistant high-grade tumors, potentiation of UCP2 repression fails to occur, contributing to impaired cell differentiation. Together, such aberrations confer a striking selective advantage on the one hand by alleviating oxidative stress-mediated cellular damage and on the other by enabling cancer cells to surmount Ca 2 þ -mediated growth-suppressive differentiation and death-inducing signals, thereby tipping the balance toward a higher proliferation index.
Results
Differential expression of UCP2 in primary breast cancer of varying histological grades. Immunolocalization of anti-UCP2 antibody on 234 primary breast tumor tissue cores showed strong mitochondrial staining in the majority of moderate and poorly differentiated tumors (grades 2 and 3, respectively). Minimal to no immunostaining was observed in over 60% well-differentiated (grade 1) tumors (Table 1) . Tissue array-based UCP2 expression ( Figure 1a ) was verified in full-sized tumor sections, wherever available. Spot checking of UCP2-negative tumors for an independent gene product, ITGA6, confirmed overall tissue integrity (data not shown).
On comparing genomic expression profiling data 18 between 16 novel cell lines of varying grade developed in our laboratory and 51 breast epithelial cell lines established by others, unlike UCP2, all other UCP family members were not differentially expressed in high versus low/intermediate-grade cell lines. UCP2 was consistently overexpressed in grade 3 cell lines, whereas minimal to no expression was observed in grade 1 and some grade 2 lines. A representative subset of four grade 3 and four grade 1 and 2 primary breast cancer cell lines was used for further phenotypic and functional studies. Gradeassociated differential expression of UCP2 transcripts was confirmed by two independent quantitative real-time PCR (QPCR) approaches (Figure 1b) , wherein cancer cell expression was normalized to that of reduction mammoplastyderived nonmalignant primary breast epithelial cell cultures. Differential UCP2 expression was maintained at the protein level in cell lysates (Figure 1b) , as well as in cell-by-cell microscopic analysis (Figure 1c ). Anti-UCP2 and mitochondrial-specific dye, MitoTracker Red, were colocalized in the mitochondria of tumor cells (Supplementary Figure S1) .
The UCP2 overexpression-induced loss of differentiation was functionally observed as the abrogation of polarity within multicellular units developed from single cell suspensions in the three-dimensional growth matrix, Matrigel. Grade 3 tumor colonies generally formed random, disoriented cell aggregates, denoted as the apolar phenotype ( Figure 1d , left panels), whereas a polarized pattern was characteristically displayed by colonies of nonmalignant and grade 1 or 2 tumor cells. UCP2 knockdown (KD) in grade 3 cells resulted in the restoration of a polarized pattern of colony growth, reflected as basal redistribution of a-6 integrin and acini-like orientation of nuclei (Figure 1d , right panels). A statistically significant inverse association was observed between UCP2 expression and polarized growth patterns, characteristic of well-differentiated acinar structures in the mammary gland (Figure 1e ).
UCP2 overexpression reflects grade-associated TGFb resistance and altered proliferation and differentiation signaling. The TGFb exposure inhibited cell proliferation in grade 1 and 2 cell lines within 24 h. Such changes were not observed in grade 3 cell lines (Figure 2a, left panel) . Unlike the rapid onset of TGFb-induced growth arrest, senescencelike morphological changes were detected on day 6 of exposure, but only in grade 1 cells (Figure 2a, right panel) .
The TGFb treatment led to further repression of UCP2 transcript levels in grade 1 and 2 but not in multiple grade 3 lines. In addition, expression of TGFb target genes CMYC, CEACAM6, WNT5B, ESDN, TGFb1R and TGFb2R was altered, whereas that of four control housekeeping genes ACTNB, GAPDH, G6PD and ALDOA were unchanged (Figure 2b ). Together, these data provide evidence for TGFb-mediated UCP2 repression. Furthermore, experimentally introduced UCP2 led to a striking neutralization of TGFb effects on cell morphology and growth in responsive tumor cells (Figure 2c ).
For further evaluation of UCP2 regulation by TGFb/SMAD, the 3 kb human UCP2 promoter was analyzed by Vector NTI Suite software (Invitrogen, Carlsbad, CA, USA). Over 20 putative RSBE-like sites were revealed, and 5 regions that displayed the highest density of such sites are shown diagrammatically (Figure 2d, top panel) . In vivo binding of SMAD4 (co-SMAD) to these regions was evaluated in grade 1 cells by chromatin immunoprecipitation (ChIP). A comprehensive role for UCP2 overexpression in the maintenance of the poorly differentiated phenotype of primary breast cancer. To evaluate additional differential effects imparted by UCP2 expression in the manifestation of histological grade, relative endogenous ROS levels were measured in cell lines of varying grade. Grade 3 cell lines displayed lower baseline ROS levels than grades 1 and 2 (Supplementary Figure S3) . Mean fluorescence intensity (MFI) measurements of C400 in UCP2-KD variants of these cell lines displayed a significant increase in ROS levels (2 to 3.5-fold, Figure 4a ). Conversely, UCP2 transduction into grade 1 cells led to further ROS reduction (data not shown). To ascertain that UCP2-regulated ROS originated in the mitochondria, a mitochondrial superoxide-specific dye, MitoSOX Red, was used in combination with the MitoTracker, MitoFluor Green. In two independent UCP2-KD grade 3 lines, a significant induction in mitochondrial superoxide levels was observed microscopically (Figure 4b ). Transfection efficiencies 495% were achieved in the cell lines used (Supplementary Figure S4a) . For additional confirmation of the mitochondrial origin of increased ROS, live tumor cells were treated with the mitochondrial complex-3 inhibitor, antimycin A, and superoxide production was measured at 1 min intervals by time-lapse imaging. As expected, superoxide induction occurred in all cell lines, regardless of UCP2 status (Supplementary Figure S4b) . Evaluation of mitochondrial superoxide regulation under such experimental conditions showed that, although baseline differences between control and UCP2-KD cells were not evident at the outset, antimycin A treatment significantly enhanced mitochondrial superoxide production in UCP2-KD cells sampled at 5, 10 and 15 min after treatment (Figure 4c ). Such differences for MitoFluor Green were not observed in the fluorescence-activated cell sorting (FACS) analysis (data not shown). Supportive evidence for an inverse association between UCP2 expression and ROS-induced growth suppression was shown by antioxidant-mediated alleviation in UCP2-KD grade 3 tumor cells (Figure 4d ). The combined observations strongly support the conclusion that UCP2 overexpression in grade 3 cell lines negatively regulates endogenous ROS levels, thereby promoting tumor cell survival under conditions of microenvironmental stress.
In yet another approach, we examined the association between UCP2 and basal [Ca 2 þ ]m (mitochondrial Ca 2 þ ) levels in primary breast tumor cell lines of varying histological grade. The rationale underlying these experiments was that As the above-mentioned physiological changes strongly influence cell cycle and cell proliferation, we evaluated the effects of UCP2-KD directly on the propagation of grade 3 cell lines. A fourfold reduction was observed in cells positive for the proliferation marker, Ki-67 (Supplementary Figure S5) (Figure 5d ). Taken together, our data are a robust and comprehensive demonstration of aggressive phenotypes conferred on poorly differentiated tumors by UCP2 overexpression. Equally important are the observations that such malignant phenotypes are significantly repressed in well and moderately differentiated primary breast cancer cells, which exhibit intact signaling of pathways that regulate UCP2 expression. A schematic illustration in Figure 6 summarizes our extensive findings, portraying for the first time the potential functional role of UCP2 within a contextual framework of histological grade of primary breast cancer. 20 ), their involvement in tumor progression is imperative. Our comprehensive analysis, focused on mitochondrial function in the context of histological grade of primary breast cancer, has revealed that both endogenous and experimentally induced UCP2 serve to reduce [Ca 2 þ ]m and ROS levels while maintaining mitochondrial membrane potential (Dcm). Thus, alleviation of oxidative stress resulting from the higher metabolic rate, characteristic of rapidly proliferating high-grade tumor cells, seems to be an adaptation facilitated by UCP2 overexpression.
Assisted through the development and application of novel breast cancer model systems, our data show that UCP2 overexpression facilitates obliteration of cell differentiation signals, particularly those imparted through the TGFb epithelial differentiation master switch. On the basis of these observations, it could be surmised that as TGFb is a growthinhibitory, pro-apoptotic peptide, execution of its effects would be incompatible with the simultaneous overexpression of antiapoptotic molecules, such as UCP2, within the same cells. In TGFb-responsive breast epithelial cells, induction of TGFb receptors by their cognate ligand directly activates SMAD proteins including SMAD1, SMAD2, SMAD3, SMAD5 and SMAD8, which in turn form transcriptional complexes to regulate TGFb target genes. In the capacity of a co-SMAD, SMAD4 has a pivotal role in mediating the anti-mitogenic and pro-apoptotic effects of TGFb (reviewed in Massagué et al. 21 ). Consistent with this function, SMAD4 expression is often lower in breast cancer than in the surrounding nonmalignant epithelium. 22 Our data underscores the significance of RSBEs within the UCP2 promoter by (1) a demonstration of RSMAD binding within this region and (2) the induction of UCP2 Evidence suggests that a major function of UCP2 is to attenuate mitochondrial production of free radicals and protect against oxidative damage. As suggested by some reports, an underlying mechanism in this regard is that UCP2-mediated uncoupling reduces the proton-motive force and Dcm, leading to ROS reduction at the expense of oxidative phosphorylation. 2, 3, 8 Our observations in spontaneously overexpressing grade 3 tumor cells, as well as in experimentally induced variants of lower histological grade, support a positive association between UCP2 and Dcm, the implication being that rather than functioning as an uncoupler, UCP2 is involved in the maintenance of Dcm. Our observations are consistent with the well-known fact that a decline in Dcm is a prelude to cell death, 11 and would thus be uncharacteristic of aggressive UCP2 overexpressing tumor cells. A similar association between UCP2 and Dcm was observed in cardiomyocytes 9 and cortical neurons 10 exposed to oxidative stress. An enhanced Dcm displayed by cancer cell lines, in comparison with noncancerous cells, 11 suggests a direct relationship between this phenotype and malignancy. This finding is in close agreement with earlier microscopic observations of the preferential retention of cationic lipophilic drugs within mitochondria of cancer cell lines and tumor cells in fresh surgical breast cancer specimens. 23, 24 It would also seem that in live tumor cells, wherein ATP is being continually synthesized, mitochondria are already in a non-maximum state of membrane potential. Thus, a further drop in Dcm to alleviate ROS is deemed unnecessary. 20 If UCP2 does not operate by uncoupling, as shown by its positive correlation with Dcm, how does it diminish ROS? Two scenarios could be discussed. As we have shown, one possibility is that it regulates the entry of Ca 2 þ into the mitochondria, which is known to enhance ROS generation, and trigger the opening of the mitochondrial permeability transition pore, thereby leading to apoptosis. [25] [26] [27] Consistent with the role of Ca 2 þ in ROS generation are the observations that [Ca 2 þ ]m uptake is Dcm dependent 28 and controls energy production. 29 Theoretically, stimulation of the tricarboxylic acid cycle and oxidative phosphorylation by Ca 2 þ consumes more O 2 , resulting in greater respiratory chain electron leakage (or ROS). UCP2-induced inhibition of mitochondrial Ca 2 þ overload and membrane depolarization is suggested by some, 30 whereas others have proposed that UCP2 is essential for [Ca 2 þ ]m uptake. 31 As shown here, UCP2 function in breast cancer cells is reminiscent of the antiapoptotic proteins, MCL1 and BCL2 known to prevent mitochondrial dysfunction and cell death, elicited by sustained high levels of intracellular calcium. 32, 33 In another scenario, the proglycolytic phenotype of cancer cells could explain UCP2-mediated ROS alleviation. One view is that microenvironmental activation of UCPs may promote the Warburg effect 34 in cancerous cell populations. 35 Thus, ROS reduction in high-grade tumor cells could be a reflection of this metabolic shift rooted in the functional mitochondrial plasticity that enhances glycolysis and permits suppression of oxidative phosphorylation. Overall, our comprehensive data unequivocally show the relationship between Ca 2 þ homeostasis and mitochondrial bioenergetics in aggressive tumor cells mediated at least partly through UCP2 overexpression.
The UCP2 activation contributes to the overall molecular basis for reprogramming of cancer cell metabolism. As many glycolytic enzymes also regulate apoptosis, and function as oncoproteins, 36 it seems likely that the glycolytic phenotype confers apoptotic resistance 37 and thereby a survival advantage. 38 Conversely, normalization of Dcm, could lead to increased apoptosis and reduced cell growth. 11 Although cancer aggressiveness associated with Dcm enhancement has been previously shown, 39 to our knowledge, this is the first experimental evidence for UCP2 participation in increasing mitochondrial membrane potential, decreasing mitochondrial Ca 2 þ overload, neutralizing oxidative stress and thereby enhancing tumor cell survival, specifically in primary tumor cells conferring poor prognosis.
Aberrant upregulation of genes commonly occurs in cancer cells, often correlated with clinical outcome, but rarely indicative of a direct role in tumor histopathology. Our unique approach of interrogating well-characterized surrogate in vitro models of clinical disease is a means of circumventing the impasse encountered by the dearth of animal models to recapitulate the biology underlying histological grade in human breast cancer. Grade-associated expression of UCP2 portrays a consistent phenotype, and a common biology between breast cancer cells in the patient host and in laboratory dishes. Functionally illustrated through pleiotropic effects ranging from metabolic reprogramming and neutralization of microenvironmental oxidative stress to circumventing apoptotic and differentiation signaling due to its overexpression in the mitochondria of high-grade breast cancer cells, UCP2 could serve as a particularly promising tumor target from the perspective of specificity and sensitivity.
Materials and Methods
Primary breast carcinoma cell culture. The development of spontaneously immortalized high-grade and nonspontaneously immortalized, hTERTtransduced low and intermediate-grade primary breast cancer cell lines has been previously described. 17 Primary tumor cell lines were routinely propagated in previously optimized low calcium MCDB170 medium supplemented with 2% fetal bovine serum. 40 Treatments included exposure to 4 ng/ml TGFb1 (R&D Systems, Minneapolis, MN, USA).
Immunolocalization. Tissue arrays comprised of formalin-fixed primary breast cancer samples obtained from the Department of Pathology, California Pacific Medical Center under IRB-approved guidelines, were deparaffinized and used for immunoperoxidase localization of a goat anti-human UCP2 antibody (cat. no. C20, Santa Cruz Biotechnology, Santa Cruz, CA, USA) according to the supplier-recommended protocol, and counterstained with nuclear fast red. Cores displaying strong cytoplasmic staining with anti-UCP2 in 430% tumor cells were scored as positive.
For immunocytochemistry, paraformaldehyde-fixed primary tumor cell lines were permeablized with Triton X-100, incubated with anti-UCP2 followed by Alexa Fluor 488 anti-goat antibody (Invitrogen), counterstained with propidium iodide (PI) and analyzed by confocal microscopy. Images from all cell lines were acquired at a constant voltage gain setting of the detector channel used. Data acquisition for no antibody control, and anti-UCP2-stained samples was performed under identical Quantitative real-time PCR. RNA isolated with the RNeasy kit (Qiagen, Valencia, CA, USA) was used to synthesize cDNA for relative gene expression analysis. UCP2 sequence-specific FAM probes (Applied Biosystems, Foster City, CA, USA) and primers (SYBR Green analysis) were used in independent QPCR assays. ACTB control was included in each PCR reaction. Relative expression of UCP2 in tumor cell lines was normalized against mean DCt values of short-term nonmalignant breast epithelial cultures (n ¼ 3). Relative expression of target genes was calculated as previously described. 17 Cell polarity. Tumor cells in six-well plates were transfected with NS siRNA or UCP2 siRNA and propagated for 7 days to form colonies from single cells in Matrigel. Transfection efficiency was measured with fluorescent siGLO RISC-free control siRNA (Thermo Scientific, Lafayette, CO, USA). Colonies were fixed and stained with anti-ITGA6 (BD Pharmingen, San Diego, CA, USA), anti-rat secondary Alexa 633, Alexa Fluor 488 phalloidin (both from Invitrogen) and PI, and examined by confocal microscopy.
Chromatin immunoprecipitation assay. A ChIP kit (Upstate) was used in conjunction with tumor cells as per manufacturer's instructions with minor modifications. Cells fixed with 1% paraformaldehyde were sonicated, followed by immunoprecipitation of DNA-SMAD4 complexes with 5 mg anti-SMAD4 antibody (Upstate). Normal rabbit IgG served as a negative control. After de-crosslinking and purification, DNA was subjected to PCR with AccuPrime Taq DNA polymerase (Invitrogen) and oligonucleotides for specific regions in the UCP2 promoter. Input controls were included in PCR reactions. PCR products were resolved on 2% agarose gels and visualized by ethidium bromide staining.
Experimental manipulation of UCP2 expression. UCP2 cDNA (ATCC, Manassas, VA, USA) was subcloned into pcDNA 3.1 using the directional TOPO Expression System (Invitrogen). In UCP2 induction studies, primary breast tumor cells were transfected either with UCP2 or empty pcDNA 3.1 vector in the presence of FuGene (Roche, Indianapolis, IN, USA) and harvested for functional assays.
For UCP2 silencing, tumor cells were transfected with siCONTROL nontargeting siRNA or a set of four human UCP2-specific siRNAs (Thermo Scientific) using Lipofectamine 2000 (Invitrogen), and evaluated 24 h later. TGFb-induced UCP2 silencing was measured by QPCR in cells treated for 24 h. In addition, cells transfected with a set of four human SMAD4-specific siRNAs (Thermo Scientific) were analyzed for UCP2 expression with and without TGFb treatment.
Measurement of Dwm. Tumor cells plated in phenol red-free growth medium were treated with vehicle or 250 mM CCCP (Sigma Aldrich), followed by exposure to vehicle or 1 mg/ml JC-1 dye (Invitrogen) for 30 min at 371C and analyzed by FACScan (BD Biosciences, San Jose, CA, USA). Green or red JC-1 fluorescence signals were resolved by detection in the FL1 and FL2 channels, respectively. Unstained cells were acquired to set the dot plot quadrants. FACScan compensation settings were adjusted with CCCP-treated cells. Experiments were carried out in triplicate and 10 000 cells were acquired for each test sample. Mitochondrial depolarization was measured by a reduction in the red/green fluorescence intensity ratio. In addition, live cell imaging was performed by confocal microscopy using red and green fluorescence filters.
Analysis of ROS.
Basal endogenous ROS accrual was measured in live tumor cell cultures loaded with the fluorogenic dye, Carboxy-H2DCFDA (5-(and-6)-carboxy-2 0 7 0 -dichlorodihydrofluorescein diacetate), also called C-400 (Invitrogen) in phenol red-free medium for 1 h followed by 30 min incubation in regular growth medium. Mitochondrial-specific superoxide production was measured by dual labeling of live cells with the fluoroprobes, MitoSOX Red and MitoFluor Green (Invitrogen) for 30 min followed by microscopic imaging. For evaluating the effects of UCP2 KD on total cellular and mitochondrial ROS levels, siRNA-transfected cells were labeled with the above-mentioned dyes. In FACS studies, intracellular oxidation of C-400 was measured in the FL1 channel. Oxidation of MitoSOX Red by superoxide was detected in FL2 and FL3 channels and MitoFluor Green in FL1. Individual control samples stained with each mitochondrial probe alone were used for equipment setup. Antimycin A (20 mM, Sigma Aldrich) was added to the cells after first microscopic image acquisition or first sample acquisition by FACS, followed by analysis at defined time points. Experiments were carried out in triplicate and 10 000 cells were acquired for each sample. ROS activity was expressed as MFI of the respective dyes.
Measurement of mitochondrial Ca 2 þ . Tumor cells plated in glassbottomed dishes in phenol red-free growth medium containing 0.1 mM Ca 2 þ were treated for 1 h at 371C with a combination of 5 mM Rhod-2 AM and 200 nM MitoFluor Green (Invitrogen). Red and green fluorescence was recorded digitally at constant voltage gain settings under a Â 60 oil immersion objective in live cells by confocal microscopy 24 h later. To study the dynamics of Ca 2 þ localization in these cells, Rhod-2 AM images were acquired by time-lapse video microscopy at 1 min intervals with a Â 60 oil immersion objective after H 2 O 2 induction, and analyzed by NIS-Elements software (Nikon, Tokyo, Japan). Data were recorded as fluorescence intensity versus time.
Cell proliferation and apoptosis Three-dimensional substrate. Relative changes in growth were measured by colony counts 1 week after plating single tumor cell suspensions in 3% Matrigel (BD Biosciences). Colonies fixed with 1:1 methanol: acetone, were incubated with anti-Ki-67 (Novocastra, Newcastle upon Tyne, UK) followed by fluorescence-tagged secondary antibody. Proliferating cells represented by green nuclei were visualized microscopically in multiple fields and counted as a percentage of all nuclei. Similarly, changes in staurosporine-induced apoptosis were measured by immunolocalization of anti-cleaved CASP3 (Cell Signaling, Danvers, MA, USA). Alternately, unfixed cells were stained with fluorescein isothiocyanate (FITC)-tagged anti-annexin V (BD Biosciences). Apoptotic index was calculated as a ratio of the percentage of apoptotic cells in untreated versus CCCP-treated tumor cell populations with and without UCP2 KD.
Two-dimensional substrate. Control or UCP2 siRNA-transfected tumor cells were incubated with 10 mM of 5-bromo-2-deoxyuridine (BrdU) for 24 h to label the proliferating population. BrdU-exposed cells were stained with anti-BrdU (Santa Cruz Biotechnology) and FITC-conjugated secondary antibody (Invitrogen) and analyzed by FACS. Alternately, cell proliferation was measured by the standard MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium-bromide; Sigma Aldrich) assay in a 96-well format, comprised of six replicates for each condition. For cell cycle distribution, 24 h after plating, cells were pulse labeled with 10 mM BrdU for 1 h and processed as mentioned above.
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